| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-81 |
DRI_Approach |
denotes |
[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia]. |
| T2 |
82-227 |
DRI_Background |
denotes |
The novel coronavirus 2019 (COVID-19) infected patients by binding human ACE2, leading to severe pneumonia and highly mortality rate in patients. |
| T3 |
228-298 |
DRI_Background |
denotes |
At present, there is no definite and effective treatment for COVID-19. |
| T4 |
299-365 |
DRI_Challenge |
denotes |
ACE2 plays an important role in the RAS, and the imbalance between |
| T5 |
382-487 |
DRI_Challenge |
denotes |
pathway and ACE2/Ang (1-7)/Mas receptor pathway in the RAS system will lead to multi-system inflammation. |
| T6 |
488-562 |
DRI_Challenge |
denotes |
Increased ACE and Ang II are poor prognostic factors for severe pneumonia. |
| T7 |
563-694 |
DRI_Challenge |
denotes |
Animal studies have shown that RAS inhibitors could effectively relieve symptoms of acute severe pneumonia and respiratory failure. |
| T8 |
695-823 |
DRI_Background |
denotes |
The binding of COVID-19 and ACE2 resulted in the exhaustion of ACE2, and then ACE2/Ang (1-7)/Mas receptor pathway was inhibited. |
| T9 |
824-932 |
DRI_Approach |
denotes |
The balance of the RAS system was broken, and this would lead to the exacerbation of acute severe pneumonia. |
| T10 |
933-1155 |
DRI_Challenge |
denotes |
Therefore, we speculate that ACEI and AT1R inhibitors could be used in patients with COVID-19 pneumonia under the condition of controlling blood pressure, and might reduce the pulmonary inflammatory response and mortality. |
